Explore the words cloud of the SweetAim project. It provides you a very rough idea of what is the project "SweetAim" about.
The following table provides information about the project.
TEL AVIV UNIVERSITY
|Coordinator Country||Israel [IL]|
|Total cost||1˙479˙995 €|
|EC max contribution||1˙479˙995 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2016-12-01 to 2021-11-30|
Take a look of project's partnership.
|1||TEL AVIV UNIVERSITY||IL (TEL AVIV)||coordinator||1˙479˙995.00|
Immunotherapy recently became an important alternative to conventional treatment regimes, yet cancer remains a universal leading cause of death. Thus, novel cancer theranostic approaches are still much desired. Although altered cell surface glycosylation is one of the hallmarks of cancer, targeting this ‘sweet aim’ for cancer therapy has been elusive, largely due to carbohydrates poor immunogenicity and the low affinity of antibodies against them. A red meat-derived carbohydrate antigen is a novel immunogenic moiety providing a key to unlock the theranostic potential of tumor-associated carbohydrate antigens. This foreign non-human sugar can be acquired only through the diet and subsequently appears on diverse cell surface glycoconjugates as ‘self’, accumulating mostly on carcinomas, and resulting in a polyclonal xeno-autoantibodies response. I have shown that such antibodies have both diagnostic and therapeutic potential, although basic understanding of their specificity and potency is scarce. The primary objective of this proposal is to design a novel personalized cancer therapeutic approach based on xeno-autoantibodies against the dietary sugar antigen. We propose an innovative interdisciplinary approach crossing the boundaries of cancer research, glycosciences, immunology and nanotechnology, with cutting-edge technologies, to design, engineer, screen and fully investigate potent targeting of ‘SweetAim’ moieties. Our discovery line is based on a two-arms platform to generate optimized antibodies for passive/active therapy, together with refined tumor cells through glyco-engineering/reprogramming for unveiling novel theranostics, finally evaluated both in vitro and in vivo. I expect our groundbreaking achievements will lead to promising new clinical tools, particularly for cancer, but also for other chronic inflammation-mediated diseases. Importantly, it will establish fundamental new concepts regarding carbohydrate recognition and response by the immune system.
|year||authors and title||journal||last update|
Madhuri Gade, Catherine Alex, Shani Leviatanâ€…Ben-Arye, JoÃ£o T. Monteiro, Sharon Yehuda, Bernd Lepenies, Vered Padler-Karavani, Raghavendra Kikkeri
Microarray Analysis of Oligosaccharide-Mediated Multivalent Carbohydrate-Protein Interactions and Their Heterogeneity
published pages: 1170-1177, ISSN: 1439-4227, DOI: 10.1002/cbic.201800037
Shani Leviatan Ben-Arye, Christoph Schneider, Hai Yu, Salam Bashir, Xi Chen, Stephan von Gunten, Vered Padler-Karavani
Differential Recognition of Diet-Derived Neu5Gc-Neoantigens on Glycan Microarrays by Carbohydrate-Specific Pooled Human IgG and IgA Antibodies
published pages: 1565-1574, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.9b00273
|Bioconjugate Chemistry 30/5||2019-08-29|
Eliran Moshe Reuven, Shani Leviatan Ben-Arye, Hai Yu, Roberto Duchi, Andrea Perota, Sophie Conchon, Shirley Bachar Abramovitch, Jean-Paul Soulillou, Cesare Galli, Xi Chen, Vered Padler-Karavani
Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy
published pages: 2936-2947, ISSN: 1936-0851, DOI: 10.1021/acsnano.8b07241
|ACS Nano 13/3||2019-08-29|
Salam Bashir, Shani Leviatan Ben Arye, Eliran Moshe Reuven, Hai Yu, Cristina Costa, Manuel GaliÃ±anes, Tomaso Bottio, Xi Chen, Vered Padler-Karavani
Presentation Mode of Glycans Affect Recognition of Human Serum anti-Neu5Gc IgG Antibodies
published pages: 161-168, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.8b00817
|Bioconjugate Chemistry 30/1||2019-08-29|
Preston S. K. Ng, Christopher J. Day, John M. Atack, Lauren E. Hartley-Tassell, Linda E. Winter, Tal Marshanski, Vered Padler-Karavani, Ajit Varki, Stephen J. Barenkamp, Michael A. Apicella, Michael P. Jennings
Nontypeable Haemophilus influenzae Has Evolved Preferential Use of N- Acetylneuraminic Acid as a Host Adaptation
published pages: , ISSN: 2150-7511, DOI: 10.1128/mbio.00422-19
Chethan D. Shanthamurthy, Prashant Jain, Sharon Yehuda, JoÃ£o T. Monteiro, Shani Leviatan Ben-Arye, Balamurugan Subramani, Bernd Lepenies, Vered Padler-Karavani, Raghavendra Kikkeri
ABO Antigens Active Tri- and Disaccharides Microarray to Evaluate C-type Lectin Receptor Binding Preferences
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-24333-y
|Scientific Reports 8/1||2019-06-13|
Anu Paul, Vered Padler-Karavani
Evolution of sialic acids: Implications in xenotransplant biology
published pages: e12424, ISSN: 0908-665X, DOI: 10.1111/xen.12424
Ron Amon, Shani Leviatan Ben-Arye, Limor Engler, Hai Yu, Noha Lim, Ludmilla Le Berre, Kristina M. Harris, Mario R. Ehlers, Stephen E. Gitelman, Xi Chen, Jean-Paul Soulillou, Vered Padler-Karavani
Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.23096
Ron Amon, Oliver C. Grant, Shani Leviatan Ben-Arye, Spandana Makeneni, Anita K. Nivedha, Tal Marshanski, Christoffer Norn, Hai Yu, John N. Glushka, Sarel J. Fleishman, Xi Chen, Robert J. Woods, Vered Padler-Karavani
A combined computational-experimental approach to define the structural origin of antibody recognition of sialyl-Tn, a tumor-associated carbohydrate antigen
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-29209-9
|Scientific Reports 8/1||2019-04-18|
Glycan Microarray Reveal the Sweet Side of Cancer Vaccines
published pages: 1446-1447, ISSN: 2451-9456, DOI: 10.1016/j.chembiol.2016.12.002
|Cell Chemical Biology 23/12||2019-08-29|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SWEETAIM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SWEETAIM" are provided by the European Opendata Portal: CORDIS opendata.